Patents by Inventor Sean LANDRETTE

Sean LANDRETTE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy with apilimod and glutamatergic agents
    Patent number: 11957688
    Abstract: Provided are compositions and methods related to the use of apilimod in combination with glutamatergic agents for treating neurological diseases and disorders, and for the treatment of cancer.
    Type: Grant
    Filed: July 12, 2022
    Date of Patent: April 16, 2024
    Assignee: OrphAl Therapeutics Inc.
    Inventors: Henri Lichenstein, Sean Landrette, Peter Ronald Young, Jonathan M. Rothberg
  • COMBINATION THERAPY WITH APILIMOD AND GLUTAMATERGIC AGENTS
    Publication number: 20230069069
    Abstract: Provided are compositions and methods related to the use of apilimod in combination with glutamatergic agents for treating neurological diseases and disorders, and for the treatment of cancer.
    Type: Application
    Filed: July 12, 2022
    Publication date: March 2, 2023
    Applicant: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Sean Landrette, Peter Ronald Young, Jonathan M. Rothberg
  • Combination therapy with apilimod and glutamatergic agents
    Patent number: 11439649
    Abstract: Provided are compositions and methods related to the use of apilimod in combination with glutamatergic agents for treating neurological diseases and disorders, and for the treatment of cancer.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: September 13, 2022
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Sean Landrette, Peter R. Young, Jonathan M. Rothberg
  • Apilimod compositions and methods for using same
    Patent number: 11266654
    Abstract: The present invention relates to methods for treating cancer with apilimod and related compositions and methods.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: March 8, 2022
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Sophia Gayle, Neil Beeharry, Paul Beckett, Sean Landrette, Chris Conrad, Matt Dyer, Tian Xu
  • Apilimod compositions and methods for using same in the treatment of renal cancer
    Patent number: 11166944
    Abstract: The present disclosure relates to methods for treating renal cancer with apilimod and related compositions and methods.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: November 9, 2021
    Assignee: AI Therapeutics, Inc.
    Inventors: Neil Beeharry, Sophia Gayle, Sean Landrette, Paul Beckett, Chris Conrad, Tian Xu, Jonathan M. Rothberg, Henri Lichenstein
  • ANTI-VIRAL COMPOSITIONS AND METHODS OF USE
    Publication number: 20210244743
    Abstract: The present invention relates to PIKfyve inhibitors, such as apilimod, and related compositions and methods for treating or preventing coronavirus infections.
    Type: Application
    Filed: February 3, 2021
    Publication date: August 12, 2021
    Inventors: Sean Landrette, Peter R. Young, Henri Lichenstein, Murat Gunel
  • COMBINATION THERAPY WITH APILIMOD AND GLUTAMATERGIC AGENTS
    Publication number: 20210077502
    Abstract: Provided are compositions and methods related to the use of apilimod in combination with glutamatergic agents for treating neurological diseases and disorders, and for the treatment of cancer.
    Type: Application
    Filed: August 7, 2020
    Publication date: March 18, 2021
    Inventors: Henri Lichenstein, Sean Landrette, Peter R. Young, Rothberg M. Jonathan
  • PIKFYVE INHIBITORS FOR CANCER THERAPY
    Publication number: 20210077500
    Abstract: The present disclosure relates methods for treating a cancer having activated MET or RAS pathway signaling using an inhibitor of PIKfyve, alone or in combination with a MET inhibitor or a RAS pathway inhibitor, and related compositions and methods to identify PIKfyve inhibitor sensitive cancers for targeted treatment.
    Type: Application
    Filed: September 10, 2020
    Publication date: March 18, 2021
    Inventors: Sean Landrette, Neil Beeharry, Peter R. Young, Jonathan M. Rothberg, Tian Xu, Henri Lichenstein
  • METHOD FOR TREATING CANCER USING HSP90 INHIBITORS
    Publication number: 20210030759
    Abstract: The disclosure also provides compositions and methods related to combination therapy with HSP90 inhibitors and BCL-2 pathway inhibitors for treating cancer. The disclosure also provides compositions and methods related to the use of ‘low dose’ HSP90 inhibitors in the treatment of cancer, alone and in combination with other therapeutic agents.
    Type: Application
    Filed: September 23, 2020
    Publication date: February 4, 2021
    Inventors: Neil Beeharry, Marylens Hernandez, Sean Landrette, Tian Xu, Jonathan M. Rothberg, Henri Lichenstein
  • ANTI-VIRAL COMPOSITIONS CONTAINING PIKFYVE INHIBITORS AND USE THEREOF
    Publication number: 20200360397
    Abstract: The present invention relates to compositions containing a PIKfyve inhibitor, preferably apilimod, APY0201 or YM-201636, most preferably apilimod, for use in treating or preventing viral infections, preferably Ebola or Marburg virus infections. It also relates to a pharmaceutical pack or kit comprising apilimod and at least one additional anti-viral agent.
    Type: Application
    Filed: July 1, 2020
    Publication date: November 19, 2020
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Neil Beeharry, Paul Beckett, Sean Landrette, Chris Conrad
  • Methods for treating cancer using HSP90 inhibitors
    Patent number: 10799508
    Abstract: The disclosure also provides compositions and methods related to combination therapy with HSP90 inhibitors and BCL-2 pathway inhibitors for treating cancer. The disclosure also provides compositions and methods related to the use of ‘low dose’ HSP90 inhibitors in the treatment of cancer, alone and in combination with other therapeutic agents.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: October 13, 2020
    Assignee: A1 Therapeutics, Inc.
    Inventors: Neil Beeharry, Marylens Hernandez, Sean Landrette, Tian Xu, Jonathan M. Rothberg, Henri Lichenstein
  • APILIMOD COMPOSITIONS AND METHODS FOR USING SAME IN THE TREATMENT OF RENAL CANCER
    Publication number: 20200297706
    Abstract: The present disclosure relates to methods for treating renal cancer with apilimod and related compositions and methods.
    Type: Application
    Filed: November 26, 2019
    Publication date: September 24, 2020
    Inventors: Neil Beeharry, Sophia Gayle, Sean Landrette, Paul Beckett, Chris Conrad, Tian Xu, Jonathan M. Rothberg, Henri Lichenstein
  • Apilimod for use in the treatment of melanoma
    Patent number: 10765682
    Abstract: The present invention relates to methods for treating melanoma with apilimod and related compositions and methods.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: September 8, 2020
    Assignee: AI Therapeutics, Inc.
    Inventors: Neil Beeharry, Sophia Gayle, Sean Landrette, Paul Beckett, Chris Conrad, Tian Xu, Jonathan M. Rothberg, Henri Lichenstein
  • APILIMOD COMPOSITIONS AND METHODS FOR USING SAME
    Publication number: 20200268764
    Abstract: The present invention relates to methods for treating cancer with apilimod and related compositions and methods.
    Type: Application
    Filed: December 27, 2019
    Publication date: August 27, 2020
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Sophia Gayle, Neil Beeharry, Paul Beckett, Sean Landrette, Chris Conrad, Matt Dyer, Tian Xu
  • Combination therapy with apilimod and glutamatergic agents
    Patent number: 10751345
    Abstract: Provided are compositions and methods related to the use of apilimod in combination with glutamatergic agents for treating neurological diseases and disorders, and for the treatment of cancer.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: August 25, 2020
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Sean Landrette, Peter R. Young, Jonathan M. Rothberg
  • THERAPEUTIC METHODS RELATING TO HSP90 INHIBITORS
    Publication number: 20200253979
    Abstract: The disclosure provides methods for treating cancer, including but not limited to, hematopoietic and lung cancers, using the HSP90 inhibitor, MPC-0767, as monotherapy and in combination therapy with additional active agents, including but not limited to, inhibitors of Bcl-2, EZH2 inhibitors, Ras/Raf/MEK/ERK pathway inhibitors, checkpoint inhibitors, DNMT inhibitors, ATO and chemotherapeutic agents. The disclosure also provides related compositions and methods of use.
    Type: Application
    Filed: February 5, 2020
    Publication date: August 13, 2020
    Inventors: Henri Lichenstein, Neil Beeharry, Sean Landrette, Sophia Gayle, Jeff Grotzke, Marylens Hernandez, Peter R. Young, Jonathan M. Rothberg
  • Anti-viral compositions containing PIKfyve inhibitors and use thereof
    Patent number: 10729694
    Abstract: The present invention relates to compositions containing a PIKfyve inhibitor, preferably apilimod, APY0201 or YM-201636, most preferably apilimod, for use in treating or preventing viral infections, preferably Ebola or Marburg virus infections. It also relates to a pharmaceutical pack or kit comprising apillimod and at least one additional anti-viral agent.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: August 4, 2020
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Neil Beeharry, Paul Beckett, Sean Landrette, Chris Conrad
  • Compositions and methods relating to the radioprotective effects of apilimod
    Patent number: 10702534
    Abstract: The present disclosure relates to methods for preventing or treating a radiation-induced disease, disorder, or condition by administering apilimod to a subject in need thereof, and related compositions.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: July 7, 2020
    Assignee: AI Therapeutics, Inc.
    Inventors: Sean Landrette, Tian Xu, Jonathan M. Rothberg, Henri Lichenstein
  • Compositions and methods of using transposons
    Patent number: 10407734
    Abstract: The present invention provides compositions and methods of using transposons. In one aspect, methods are disclosed that are useful for identifying negatively selected genes in an insertional mutagenesis screen. In another aspect, compositions for reducing proliferation of a tumor cell expressing an oncogenic RAS include an activator of a WNT pathway. Pharmaceutical compositions for reducing proliferation of tumor cells in a subject in need thereof by administering an effective amount of an activator of a WNT pathway to the tumor cells of the subject are also disclosed.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: September 10, 2019
    Assignee: Yale University
    Inventors: Tian Xu, Feng Qian, Sean Landrette
  • COMBINATION THERAPY WITH APILIMOD AND GLUTAMATERGIC AGENTS
    Publication number: 20190255061
    Abstract: Provided are compositions and methods related to the use of apilimod in combination with glutamatergic agents for treating neurological diseases and disorders, and for the treatment of cancer.
    Type: Application
    Filed: February 20, 2019
    Publication date: August 22, 2019
    Inventors: Henri Lichenstein, Sean Landrette, Peter R. Young, Jonathan M. Rothberg